CD40LG and COVID-19: Study subjects were identified either after routine serology testing or occupational health screening in the Stanford Health Care Clinical Laboratories for anti-SARS-CoV-2 RBD IgM and IgG antibodies (136 asymptomatic individuals or outpatients), or after they reported to Stanford Health Care-associated clinical sites with symptoms of COVID-19.